** Shares of diagnostics firm Trinity Biotech TRIB.O rise 5.5% to 67 cents

** Says upgraded EpiCapture test met its main goal of accurately flagging aggressive prostate cancer, a common cancer in men that can spread quickly if not treated

** Test uses a urine sample instead of scans or needle biopsies and applies machine learning to combine DNA markers with patient factors such as ethnicity, TRIB says

** Says this aims to better reflect real-world differences in how prostate cancer affects different groups

** Study included about 750 patients from diverse backgrounds; test showed about 85% accuracy, which company says is strong for cancer diagnostics

** Plans a U.S. rollout as a lab-developed test through its New York reference laboratory

** Shares down ~10% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))